In February 2024, the US Food and Drug Administration (FDA) approved Xolair (omalizumab; Genentech, Inc), an anti-immunoglobulin E (IgE) antibody, for the treatment of IgE-mediated food allergies in ...
Xolair (omalizumab) is a prescription drug used to treat chronic (ongoing) hives without a known cause. Xolair is a biologic drug and does not come in a biosimilar version. It’s used when symptoms ...
Xolair is a branded injectable medication used to treat allergic asthma, chronic hives, and rhinosinusitis. It’s recently been approved to manage food allergies, reducing the risk of serious reactions ...
Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. Two weeks ago, the Food and Drug Administration approved Xolair ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new positive data from Stage 2 and Stage 3 of the National Institutes ...
In children with immunoglobulin E (IgE)-mediated food allergy, most oral food challenges (OFCs) performed during ongoing treatment with omalizumab reached clinically meaningful tolerable doses, and ...
Food allergies are common and are associated with substantial morbidity; the only approved treatment is oral immunotherapy for peanut allergy. In this trial, we assessed whether omalizumab, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results